4-(2-indol-3-yl-ethylcarbamoyl)-butyric acid | 4962-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-(2-indol-3-yl-ethylcarbamoyl)-butyric acid
• 英文别名: 4-[2-(1H-3-indolyl)ethylcarbamoyl]-butanoic acid；5-oxo-5-[2-(3-indolyl)ethyl]aminovaleric acid；N-<2-(Indol-3-yl)-ethyl>glutarsaeure-monoamid；5-{[2-(1H-indol-3-yl)ethyl]amino}-5-oxopentanoic acid；5-[2-(1H-indol-3-yl)ethylamino]-5-oxopentanoic acid
• CAS: 4962-71-4
• 化学式: C₁₅H₁₈N₂O₃
• 分子量: 274.32
• InChiKey: ADNUGOGDMFDOTO-UHFFFAOYSA-N

物化性质

• 熔点：
  135-137 °C
• 沸点：
  627.7±45.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  82.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-indol-3-yl-ethylcarbamoyl)-butyric acid 在 盐酸 、 sodium tetrahydroborate 、 氯化亚砜 、 sodium hydride 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 、 三氟乙酸 、 三氯氧磷 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 11.0h， 生成 4-((4-oxo-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizin-12(2H)-yl)methyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)benzamide
  参考文献：
  名称：

  Marbostat-100定义了一类新的有效的选择性抗炎和抗风湿组蛋白去乙酰化酶6抑制剂

  摘要：

  组蛋白脱乙酰基酶（HDAC）家族的表观遗传修饰剂有助于自身免疫，癌症，HIV感染，炎症和神经变性。因此，可改变蛋白质乙酰化，基因表达模式和细胞命运决定的组蛋白脱乙酰基酶抑制剂（HDACi）代表了有望用于治疗这些疾病的新药。而pan-HDACi抑制所有11 Zn 2+依赖的组蛋白脱乙酰基酶（HDACs）并引起广泛的副作用，组蛋白脱乙酰基酶6（HDAC6i）的特定抑制剂被认为副作用较小。我们介绍了新型的HDAC6i Marbostats的合成和生物学评估，该新型HDAC6i包含与四氢-β-咔啉衍生物连接的异羟肟酸部分。我们的先导化合物Marbostat-100在体外以及在细胞中均比以前确立的特征明确的化合物更有效，更选择性的HDAC6i。此外，Marbostat-100被小鼠很好地耐受，并且对II型胶原诱导的关节炎有效。因此，Marbostat-100代表了最具有选择性的已知HDAC6i，并且

  DOI：

  10.1021/acs.jmedchem.7b01593
• 作为产物：
  描述：

  戊二酸酐 、 色胺 以 二氯甲烷 为溶剂， 反应 0.33h， 生成 4-(2-indol-3-yl-ethylcarbamoyl)-butyric acid
  参考文献：
  名称：

  新型超分子钯催化剂，用于水介质中亚胺的不对称还原

  摘要：

  基于由β-环糊精/亚胺作为酶模拟物和氢化钯作为还原剂形成的超分子冻干复合物，描述了一种将二氢-β-咔啉衍生物不对称还原为相应的四氢-β-咔啉的新方法。该方法使我们能够开发出一种短而有效的（R）-甜菜碱和（R）-十倍体碱生物碱的制备方法，分别具有89％和90％的高总收率和ee。

  DOI：

  10.1021/ol9011772

文献信息

• [EN] NOVEL HDAC6 INHIBITORS AND THEIR USES<br/>[FR] NOUVEAUX INHIBITEURS DE HDAC6 ET LEURS UTILISATIONS
  申请人：UNIVERSITÄT REGENSBURG

  公开号：WO2016020369A1

  公开（公告）日：2016-02-11

  The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H − L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6).

  本发明涉及小分子化合物及其作为HDAC抑制剂的用途以及在治疗各种疾病（如癌症）中的应用。本发明还涉及合成这些化合物的方法和治疗方法。H - L（HA），其中H是从（头基团1）、（头基团2）、（头基团3）、（头基团4）、（头基团5）和（头基团6）中选择的头基团。
• AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
  申请人：OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

  公开号：US20170183318A1

  公开（公告）日：2017-06-29

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医学，包括一种用于预防和治疗由RNA-和DNA-含病毒引起的疾病以及相关疾病的方法，其中该方法包括使用通式I的化合物或其药用可接受盐的有效量。该发明还涉及制备上述化合物的方法，用于预防或治疗由RNA-和DNA-含病毒引起的疾病的药物组合物，该组合物包括通式I的化合物或其药用可接受盐的有效量。该发明解决了提供一种新型药剂的目标，用于治疗属于肠病毒、副呼吸道病毒、呼吸道病毒、呼吸道病毒或阿尔法冠状病毒属的RNA-含病毒引起的疾病，和/或属于腺病毒科和/或疱疹病毒科的DNA-含病毒引起的疾病，并在预防和治疗哮喘急性发作、慢性阻塞性肺疾病、黏液囊病、结膜炎、胃肠炎、肝炎、心肌炎；在预防和治疗流涕、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道梗阻综合征方面具有有效性。
• Novel Supramolecular Palladium Catalyst for the Asymmetric Reduction of Imines in Aqueous Media
  作者：Wender A. da Silva、Manoel T. Rodrigues、N. Shankaraiah、Renan B. Ferreira、Carlos Kleber Z. Andrade、Ronaldo A. Pilli、Leonardo S. Santos

  DOI：10.1021/ol9011772

  日期：2009.8.6

  A novel approach to the asymmetric reduction of dihydro-β-carboline derivatives to the corresponding tetrahydro-β-carbolines is described based on the supramolecular lyophilized complex formed from β-cyclodextrin/imines as an enzyme mimetic and palladium hydride as the reducing agent. The methodology allowed us to develop a short and efficient preparation of (R)-harmicine and (R)-deplancheine alkaloids

  基于由β-环糊精/亚胺作为酶模拟物和氢化钯作为还原剂形成的超分子冻干复合物，描述了一种将二氢-β-咔啉衍生物不对称还原为相应的四氢-β-咔啉的新方法。该方法使我们能够开发出一种短而有效的（R）-甜菜碱和（R）-十倍体碱生物碱的制备方法，分别具有89％和90％的高总收率和ee。
• USE OF CANTHIN-6-ONE AND ITS ANALOGS IN THE TREATMENT OF MYCOBACTERIA-LINKED PATHOLOGIES ( amended
  申请人：Fournet Alain Robert Francois Maxime

  公开号：US20110059977A1

  公开（公告）日：2011-03-10

  The present invention relates to the use, for the preparation of a medicament intended for the treatment or the prevention of pathologies linked to, or caused by mycobacteria, of at least one of the compounds of the following formula (I): in which B represents in particular a nitrogen atom, and R1, R2, R3, R4, R5, R6, R7 and R8 represent in particular a hydrogen atom.

  本发明涉及使用以下式(I)中至少一种化合物，用于制备用于治疗或预防与分支杆菌相关或由其引起的病理状况的药物，其中B特别代表氮原子，而R1、R2、R3、R4、R5、R6、R7和R8特别代表氢原子。
• Antiproliferative activity of arborescidine alkaloids and derivatives
  作者：Leonardo S. Santos、Cristina Theoduloz、Ronaldo A. Pilli、Jaime Rodriguez

  DOI：10.1016/j.ejmech.2009.04.005

  日期：2009.9

  Current issues in cancer research involve searching for novel anticancer compounds that can be used to regulate the cell cycle and lead to more effective treatments of tumors. In this study, it was hypothesized that possessing a cyclic alkaloid similar to harmine, arborescidines can disrupt the proliferative state of cancer cells and block the activity of topoisomerases. The antiproliferative activity of arborescidines A-C and their derivatives was evaluated in vitro against four human tumor cell lines: gastric adenocarcinoma, lung cancer, bladder carcinoma and leukemia. Assuming the mechanism of action by topoisomerase II binding model, the compounds possessing the greatest activity had nonpolar side-chain into hydrophobic binding region on the DNA/topo II complex. (C) 2009 Elsevier Masson SAS. All rights reserved.